Sugar-Based Excipients Market Size and Share
Sugar-Based Excipients Market Analysis by Mordor Intelligence
The sugar-based excipients market size is currently valued at USD 1.57 billion and is forecast to reach USD 1.97 billion by 2030, advancing at a 4.61% CAGR. This expansion reflects rising demand for multifunctional carriers that simplify direct compression, accelerate orally disintegrating tablet (ODT) launches, and improve taste masking in pediatric and geriatric therapies. Co-processed platforms, spray-dried polyols, and 3-D-printable sugar matrices are reshaping formulation workflows while lowering manufacturing costs for generic producers. Contract development and manufacturing organizations (CDMOs) are scaling continuous direct-compression lines, further boosting adoption of sugar-derived binders and fillers. Regionally, North America retains leadership on the back of robust regulatory support, whereas Asia-Pacific registers the fastest uptake as China and India upgrade capacity for global exports. Competitive activity centers on acquisitions and joint ventures that combine excipient expertise with advanced process-analytical technologies.
Key Report Takeaways
- By product category, polyols commanded 45.51% of sugar-based excipients market share in 2024, while co-processed sugars are projected to expand at an 8.25% CAGR through 2030.
- By form, direct-compression sugars held 37.53% share of the sugar-based excipients market size in 2024 and syrups & solutions are advancing at a 7.71% CAGR to 2030.
- By dosage form, oral solids accounted for 64.12% share of the sugar-based excipients market in 2024; oral liquids are set to grow at a 7.71% CAGR over the forecast period.
- By end user, generic manufacturers captured 50.32% of the sugar-based excipients market size in 2024, whereas CDMOs record the highest projected CAGR at 8.61% through 2030.
- By geography, North America led with 39.32% revenue share in 2024 and Asia-Pacific is forecast to post a 7.51% CAGR to 2030.
Global Sugar-Based Excipients Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Increasing use of co-processed excipients | +1.2% | North America & EU, spreading globally | Medium term (2–4 years) |
| Rapid expansion of the generics industry | +0.9% | Asia-Pacific core, spill-over to Latin America | Short term (≤ 2 years) |
| Surge in ODT launches | +0.8% | Developed markets worldwide | Medium term (2–4 years) |
| Demand for palatable pediatric & geriatric drugs | +0.7% | North America & EU, extending into Asia-Pacific | Long term (≥ 4 years) |
| 3-D-printed sugar matrices for personalized dosing | +0.4% | Pilot programs in North America & EU | Long term (≥ 4 years) |
| FDA novel excipient review pilot | +0.3% | United States with global ripple effects | Medium term (2–4 years) |
| Source: Mordor Intelligence | |||
Increasing Use of Co-Processed Excipients
Co-processed sugars combine flowability, compressibility, and rapid dissolution in single particles that streamline direct compression and continuous manufacturing. The sugar-based excipients market is witnessing an 8.25% CAGR for these engineered blends as generic firms and CDMOs look to cut unit operations without sacrificing tablet robustness. Regulatory openness via the FDA Emerging Technology Program now shortens approval timelines for continuous direct-compression lines that rely on co-processed polyols, accelerating commercial uptake in North America and Europe[1]Food and Drug Administration, “News from Emerging Technology Program,” fda.gov.
Rapid Expansion of the Generics Industry
Generics manufacturers, which already absorb more than half of current sugar-based excipients market demand, require low-cost yet pharmacopoeia-compliant fillers to achieve bioequivalence quickly. Asian producers leverage domestic corn-based sorbitol and spray-dried mannitol to supply regional and export markets, pushing the sugar-based excipients market toward high-volume, flexible packaging formats that minimize freight and storage costs.
Surge in Orally Disintegrating Tablet Launches
ODTs improve adherence for patients who struggle with swallowing. Mannitol-rich blends deliver the desired mouthfeel and mechanical strength, and ready-to-use PEARLITOL Flash systems cut development time. Continuous 3-D printing of ODTs, recently cleared by the FDA, further strengthens demand for polyol-centered formulations in the sugar-based excipients market[2]Roquette, “Two-Component Simple Platform for ODT,” roquette.com.
Growing Demand for Palatable Formulations for Pediatric & Geriatric Cohorts
Up to 64% of pediatric non-adherence cases stem from unpleasant taste. Maltitol and mannitol mask bitterness while maintaining caloric neutrality and glycemic stability, enabling chocolate-based steroids and gummy formats that broaden therapeutic options. Updated EMA labeling rules underscore safety, reinforcing the role of well-characterized sugar excipients across vulnerable populations.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Stringent multi-jurisdictional regulations | -0.8% | EU-US-Japan compliance triangle | Medium term (2–4 years) |
| Hygroscopicity-driven stability challenges | -0.6% | Humid regions worldwide | Short term (≤ 2 years) |
| Volatile pharma-grade sorbitol supply chain | -0.4% | Asia-Pacific production hubs | Short term (≤ 2 years) |
| Sustainability scrutiny of high-carbon sucrose | -0.3% | EU & North America regulators | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Stringent Multi-Jurisdictional Regulatory Requirements
Divergent pharmacopoeial standards force manufacturers to run separate stability studies and maintain duplicate documentation, inflating development timelines. Recent EU updates on allergen disclosure add further complexity, requiring sugar-based excipient suppliers to validate every lot for residual proteins and heavy metals.
Hygroscopicity-Driven Stability Challenges
Polyols readily absorb ambient moisture, compromising tablet hardness and disintegrant efficiency. Investment in moisture-barrier coatings and desiccant blister packs raises cost of goods and slows scale-up for humidity-sensitive markets.
Segment Analysis
By Product: Polyols Retain Command, Co-Processing Gains Traction
Polyols account for 45.51% of sugar-based excipients market share due to their favorable compressibility, low reactivity, and familiarity among regulators. Spray-dried mannitol grades enhance flow and enable higher active loading, supporting mini-tablet and ODT formats. Actual sugars exhibit stable, niche-oriented demand in syrups and medicated confectionery. Meanwhile, the sugar-based excipients market size attributed to co-processed sugars is projected to expand at an 8.25% CAGR as formulators seek single-step solutions that deliver robust hardness and rapid dissolution. Polyol-cellulose hybrids illustrate how particle engineering delivers high bulk density with minimal dusting, translating directly into faster line speeds and lower operator exposure.
Advances in continuous direct compression technology further amplify co-processed demand by allowing feeders to meter multifunctional blends without pre-mixing. Regulatory validation under the FDA Emerging Technology Program shortens paths to commercial launch, spurring investment across both originator and generic pipelines. Suppliers that secure backward integration into raw sugar streams and invest in spray-agglomeration towers are best positioned to capture this high-margin growth pocket within the sugar-based excipients market.
Note: Segment shares of all individual segments available upon report purchase
By Form: Direct Compression Platforms Dominate While Liquid Systems Accelerate
Direct-compression sugars hold 37.53% share of the sugar-based excipients market. Spray drying, fluid-bed agglomeration, and co-spheronization techniques continue to improve compressibility and reduce lubricant sensitivity, aligning well with continuous tablet presses that operate at speeds exceeding 250,000 tablets/hour. Powders and granules still anchor conventional wet-granulation lines, but roll-compaction adoption is rising thanks to low-hygroscopic mannitol grades that withstand high shear without capping.
Conversely, syrups and solutions log a 7.71% CAGR, reflecting the market’s pivot toward patient-friendly liquid formats for pediatrics and geriatrics. Non-crystallizing sorbitol and glycerol-free maltitol solutions offer improved viscosity control and chemical stability, allowing formulators to reduce preservative loads. Single-phase aqueous concentrates simplify shipping and on-site dilution, cutting cold-chain requirements and widening access in emerging markets. This twin-track growth pattern underscores the sugar-based excipients market’s versatility across both high-speed solids and value-added liquid delivery channels.
By Functional Role: Fillers Anchor, Coatings Emerge
Fillers and diluents underpin 55.21% of current revenue as virtually every tablet requires bulking agents to achieve practical handling size. The sugar-based excipients market size for fillers grows in lock-step with oral solid output, driven by consistent pharmacopoeial acceptance and benign safety profiles. Binders such as syrup-solidified sucrose see steady uptake in controlled-release matrices where reproducible viscosity contributes to robust tablet integrity.
Coating agents deliver the strongest momentum with an 8.87% CAGR. Moisture-barrier films based on polyol-polysaccharide blends extend shelf life for hygroscopic active ingredients, while flavored coatings improve organoleptic profiles without adding artificial sweeteners. Nanothin mannitol layers created via fluid-bed deposition show promising moisture transmission rates and minimal weight gain, highlighting innovation depth in the sugar-based excipients market.
By Dosage Form: Oral Solids Prevail, Liquids Gain Ground
Oral solids dominate at 64.12% share of the sugar-based excipients market because tablets remain the most economical and stable dosage form. High-shear wet granulation and roller compaction integrate advanced mannitol polymorphs that enhance tablet hardness, facilitating mini-tablets for combination therapies. The surge in 3-D-printed oral solids introduces lattice geometries unattainable through traditional tooling, opening new vistas for personalized medicine.
Oral liquids expand at a 7.71% CAGR, powered by regulatory pushes for age-appropriate formulations and the rising prevalence of dysphagia. Multi-component syrup vehicles leveraging non-crystallizing sorbitol enable stable suspensions even at high active payloads, improving bioavailability for poorly soluble drugs. Sugar-free variants satisfy diabetic safety requirements, widening potential patient pools and adding to the sugar-based excipients market growth.
Note: Segment shares of all individual segments available upon report purchase
By End User: Generics Command, CDMOs Accelerate
Generics manufacturers account for 50.32% of sugar-based excipients market share as patent cliffs drive volume demand for cost-efficient ingredients with robust supply chains. Polyols satisfy bioequivalence criteria without altering dissolution compared with originator brands, making them the go-to choice in abbreviated new drug applications.
CDMOs, however, top growth charts at 8.61% CAGR. Their flexible asset base allows seamless integration of novel co-processed sugars and continuous mixing platforms demanded by biotech and niche pharma clients. Investments such as Hovione’s USD 170 million spray-drying capacity boost underline confidence that the sugar-based excipients market will increasingly rely on outsourced specialists for accelerated development timelines.
Geography Analysis
North America retains 39.32% of global revenue thanks to the FDA’s constructive stance on novel excipients, a deep bench of continuous manufacturing facilities, and active collaboration between academia and industry. Exclusive distribution deals, such as Univar Solutions’ agreement to supply niche cellulose-based carriers, further enrich the regional portfolio. Sustainability initiatives, exemplified by carbon-neutral blister packs derived from sugar cane, show that environmental credentials are now intertwined with excipient selection.
Europe presents a mature but innovation-driven arena. Regulatory updates on allergen labeling and a possible ban on titanium dioxide spur R&D into alternative colorants and coatings, releasing fresh opportunities for calcium-enriched sugar shells. Roquette’s USD 2.85 billion takeover of IFF Pharma Solutions marks the largest transaction in European excipients history, consolidating spray-dried polyol production under a single banner and signaling heightened competition in the sugar-based excipients market.
Asia-Pacific records the highest CAGR at 7.51%. China and India ramp up sorbitol and mannitol output, while South Korea and Singapore attract high-value biologics that require pharmaceutical-grade polyols as tonicity agents. Lotte Fine Chemical’s USD 740 million distribution pact with Colorcon positions it as the world’s largest pharmaceutical cellulose provider, underscoring the region’s strategic importance. Trade agreements under the Pharmaceutical Inspection Co-operation Scheme streamline export adherence and reinforce Asia’s role in the sugar-based excipients market.
Competitive Landscape
The sugar-based excipients market is moderately fragmented but trending toward consolidation. Roquette, ADM, and Ashland leverage acquisitions to secure raw sugar access, expand co-processing know-how, and deepen geographic footprints. Roquette’s IFF Pharma Solutions buyout adds continuous processing assets and proprietary film-coating polymers, reinforcing its leadership in the polyol segment[3]International Flavors & Fragrances, “Sale of Pharma Solutions Business,” iff.com.
Strategic collaborations complement M&A. Hovione’s joint venture with Zerion Pharma melds spray-drying expertise with drug-polymer dispersion technology, extending applicability of sugar carriers to poorly soluble molecules. Suppliers with robust process-analytical technology ecosystems, tablet press simulation capabilities, and 3-D-printing partnerships gain bargaining power with CDMOs looking for turnkey solutions.
Sustainability, supply resilience, and digital traceability emerge as new battlegrounds. Companies invest in biomass boilers, carbon-neutral logistics, and blockchain-based lot tracking to reassure clients of continuity and compliance. Those unable to certify low-carbon or GMO-free sugar streams risk exclusion from stringent EU and US supply chains, highlighting the competitive stakes ahead in the sugar-based excipients market.
Sugar-Based Excipients Industry Leaders
-
Roquette Group
-
The Lubrizol Corporation
-
DFE Pharma
-
Archer Daniels Midland
-
Ashland
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- May 2025: Roquette finalized its USD 2.85 billion acquisition of IFF Pharma Solutions, creating the world’s largest pharmaceutical excipients supplier and boosting its US footprint.
- September 2024: Ashland divested its nutraceuticals business to Turnspire Capital Partners to focus on core pharmaceutical excipient operations across North America and Latin America.
Global Sugar-Based Excipients Market Report Scope
As per the scope of the report, the excipient is a pharmacologically inert element formulated together with the active ingredient of the medication. This is done with the purpose of providing substance to the formulation, providing prevention and stability from denaturation, facilitating the absorption of drugs by a patient, and other pharmacokinetic considerations. The Sugar-Based Excipients Market is segmented by Product (Actual sugar, Sugar alcohols, and Artificial sweeteners), Type (Powders/Granules, Direct compression sugars, Crystals, and Others), Application (Fillers and Diluents, Flavoring agents, Tonicity agents, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| Actual Sugars |
| Sugar Alcohols (Polyols) |
| Artificial / High-Intensity Sweeteners |
| Co-processed Sugar Excipients |
| Powders & Granules |
| Direct-Compression Sugars |
| Crystals |
| Syrups & Solutions |
| Fillers & Diluents |
| Binders |
| Flavoring / Sweetening Agents |
| Tonicity Modifiers |
| Coating Agents |
| Oral Solid Dosage |
| Oral Liquid Dosage |
| Topical & Others |
| Branded Pharmaceutical Manufacturers |
| Generic Pharmaceutical Manufacturers |
| Nutraceutical & Dietary-Supplement Producers |
| Contract Development & Manufacturing Organisations (CDMOs) |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Product | Actual Sugars | |
| Sugar Alcohols (Polyols) | ||
| Artificial / High-Intensity Sweeteners | ||
| Co-processed Sugar Excipients | ||
| By Form | Powders & Granules | |
| Direct-Compression Sugars | ||
| Crystals | ||
| Syrups & Solutions | ||
| By Functional Role | Fillers & Diluents | |
| Binders | ||
| Flavoring / Sweetening Agents | ||
| Tonicity Modifiers | ||
| Coating Agents | ||
| By Dosage Form | Oral Solid Dosage | |
| Oral Liquid Dosage | ||
| Topical & Others | ||
| By End User | Branded Pharmaceutical Manufacturers | |
| Generic Pharmaceutical Manufacturers | ||
| Nutraceutical & Dietary-Supplement Producers | ||
| Contract Development & Manufacturing Organisations (CDMOs) | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| South Korea | ||
| Australia | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is driving growth in the sugar-based excipients market?
Rising adoption of co-processed polyols, continuous direct-compression lines, and patient-centric ODTs are the main catalysts, underpinning a 4.61% CAGR to 2030.
Which segment holds the largest sugar-based excipients market share?
Polyols dominate with a 45.51% share in 2024 thanks to their compressibility, stability, and regulatory familiarity.
Why are CDMOs important for the sugar-based excipients industry?
CDMOs post an 8.61% CAGR because they offer flexible manufacturing capacity and advanced formulation expertise that drug sponsors increasingly outsource.
Which region is expanding fastest?
Asia-Pacific leads with a 7.51% CAGR as China and India scale low-cost production and South Korea invests in high-value biologics.
How are sustainability concerns affecting the market?
EU carbon-intensity metrics and potential titanium dioxide bans pressure suppliers to develop low-carbon sugar streams, biodegradable coatings, and transparent supply chains.
Page last updated on: